Azithromycin vs doxycycline with beta-lactam in hospitalized adults with pneumonia
Official title: Azithromycin versus Doxycycline with Beta-lactam therapy in Hospitalized Adult Patients with Community Acquired Pneumonia
Funded at Mayo Clinic Rochester · NIH-11451639 · Data updated 2026-11-12
In hospitalized adults with community-acquired pneumonia, this study will compare two antibiotic combinations to see which works better and is safer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $761,573 |
| NIH project number | 1R61HL183016-01A1 |
| Project ID | NIH-11451639 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21 years and older hospitalized with community-acquired pneumonia.
✕Less likely to help
Patients whose pneumonia is due to non-bacterial causes or who have contraindications to macrolides or doxycycline may not benefit.
What this research studies
This trial tests whether azithromycin plus a beta-lactam is more effective and safer than doxycycline plus a beta-lactam for treating community-acquired pneumonia in adults. It is designed as a pragmatic, open-label randomized study using an electronic health record tool to screen and randomize patients at the point of care. The study will enroll about 1,120 participants across Mayo Clinic Rochester, with careful evaluation of how well clinicians can integrate the protocol into routine practice before expanding. Results could influence how doctors choose first-line therapy for hospitalized CAP patients.
Why it matters
Potential benefit: If successful, the findings could guide safer, more effective antibiotic choices for hospitalized CAP, potentially improving outcomes and reducing resistance.
How similar studies have gone: Prior guidelines support combination therapy, but this pragmatic trial seeks clearer comparative effectiveness in real-world hospital settings.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Gajic, Ognjen — Mayo Clinic Rochester
- Study coordinator: Gajic, Ognjen
Related research
Other NIH-funded projects on the same topics.
-
Combined immunomodulatory effect of macrolides and corticosteroids in hospitalized CAP patients
This study looks at whether adding macrolide antibiotics to steroids helps or harms people hospitalized with community-acquired pneumonia (CAP).
-
Blocking ANGPTL4 to help people with severe community-acquired pneumonia
This project will test whether blocking the blood protein ANGPTL4 helps adults hospitalized with severe community-acquired pneumonia recover faster and survive more often.
-
Pediatric pneumonia severity score (PedCAPS)
This project will create and check a simple score to predict how serious pneumonia will be in children who come to the emergency room.
-
Ketogenic diet to help muscle in older adults with pneumonia
A small trial will test if a short 10-day ketogenic (low carb, high fat) feeding helps preserve muscle and speed recovery in people 65 and older hospitalized with pneumonia.
-
Using systems biology to understand severe community-acquired pneumonia
This project analyzes patients' lung and blood samples with advanced lab tests and computer models to find biological patterns that can help guide treatment for people with severe pneumonia, including COVID-related cases.
-
Targeted antibiotic treatment for community-acquired pneumonia
This project uses faster diagnostic tests to help doctors pick and shorten antibiotics for adults hospitalized with community-acquired pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.